T
TILT Biotherapeutics
TILT Bio aims to enable T-cell treatments and immune checkpoint inhibitors with oncolytic viruses, used to boost lymphocytes and immunological checkpoint blocking antibody treatments
About TILT Biotherapeutics
Developer of a biotechnology platform intended to develop oncolytic immunotherapies that will modify the tumor microenvironment and eliminate its ability to suppress immune responses to cancer. The company's platform involves the utilization of oncolytic viruses for the enhancement of tumor cell therapy and will be used in tumor-infiltrating lymphocytes, chimeric antigen receptors, and checkpoints, enabling researchers to inhibit antibody therapy for solid tumors so as to achieve similar results. Keywords: Pharmaceuticals and BiotechnologyBiotechnology Business, Cancer Immunotherapy, Cancer Immunotherapy Product, Cell Therapy, Oncolytic Virus, T-Cell Therapy.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2013
- Headquarters
- Helsinki, Finland
- Employees
- 27
- Open positions
- None listed
- Dealroom signal
- 70.0/100
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Oncology, Immune System, Spinout, Sustainable Development Goals, EIC, Biotech and Pharma, EIC Fund, Nordic Rising Star 2022, Horizon Europe
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES BOther financing | May 2025 | $25M | $99M | Lifeline Ventures · Tesi · EIC Fund · Stephen Industries | ↗ |
| GRANTOther financing | Mar 2024 | $0 | — | European Innovation Council | — |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for TILT Biotherapeutics is 2.2K monthly website visits, up 29.4% over the last three months. TILT Biotherapeutics's team grew 0% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
European Innovation Council
US Department of War
Series A3 investors entered at this stage
Finnvera Venture Capital
Lifeline Ventures
EIC Fund
Series B and later4 investors entered at this stage
Business Finland
Tesi
Stephen Industries- AIACME Investments
Other known investors1 additional known investor
University of Helsinki
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about TILT Biotherapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See TILT Biotherapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.